An integrative view on sex differences in brain tumors by Tao Sun et al.
REVIEW
An integrative view on sex differences in brain tumors
Tao Sun1 • Anya Plutynski2 • Stacey Ward1 • Joshua B. Rubin1,3,4
Received: 26 February 2015 / Revised: 27 April 2015 / Accepted: 11 May 2015 / Published online: 19 May 2015
 The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract Sex differences in human health and disease
can range from undetectable to profound. Differences in
brain tumor rates and outcome are evident in males and
females throughout the world and regardless of age. These
observations indicate that fundamental aspects of sex de-
termination can impact the biology of brain tumors. It is
likely that optimal personalized approaches to the treat-
ment of male and female brain tumor patients will require
recognizing and understanding the ways in which the bi-
ology of their tumors can differ. It is our view that sex-
specific approaches to brain tumor screening and care will
be enhanced by rigorously documenting differences in
brain tumor rates and outcomes in males and females, and
understanding the developmental and evolutionary origins
of sex differences. Here we offer such an integrative per-
spective on brain tumors. It is our intent to encourage the
consideration of sex differences in clinical and basic sci-
entific investigations.
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Introduction
Sex differences in human development, aging, and disease
are so commonplace they sometimes seem to escape
questioning. Yet, the ways in which males and females
consistently differ have significant importance for disease
risk and prognoses, and cancer is no exception. There are
measureable differences between men and women in can-
cer prevalence, mortality, and progression. Understanding
these differences requires tracing their sources at the
molecular, cellular, tissue, organismal and evolutionary
levels, and providing an integrative explanation, one where
data from different fields are mutually instructive and
mutually constraining. This review aims at exactly this: to
show how significant sex differences in brain cancers may
be provided with an integrative explanation, drawing upon
molecular, cellular, tissue, organismal, developmental, and
evolutionary biology.
Beyond its inherent importance to normal biology, the
study of sex differences can provide a novel perspective: a
parallax view of the particular disease of interest. More-
over, it has the potential to uncover hidden elements of
pathobiology. In order for sex to affect disease phenotype,
it must affect fundamental mechanisms of risk and pro-
gression. Sex exerts its influence through differences in sex
chromosome complement, epigenetic (organizational) and
acute (activational) effects of sex hormone action, and sex-
specific maintenance or reprogramming of maternal and
paternal gene imprinting. As a consequence of these ge-
netic and epigenetic processes, males and females exhibit
different normal physiologies as well as different reactions
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to developmental, metabolic, and genotoxic stressors.
These compensatory reactions often produce further sex-
specific changes in epigenetics and gene expression that
can widen the differences between males and females for
disease risk.
Here, we will first examine sex differences in brain
tumors. We will present data regarding the predominance
of cases in males for most individual tumor types and
consider the lessons of exceptions like meningioma and
low-grade astrocytoma. Second, we will review the de-
velopmental and evolutionary basis for sex differences. It
is only through recognizing how evolution has favored
different growth optima in males and females and how the
effects that sex determination through development have
on gene expression, metabolism, growth, immune func-
tion, and homeostatic responses to stressors that we can
hope to recognize and anticipate the effects of sex in
cancer diagnosis and therapeutic responses. We will con-
clude by contemplating how incorporating the biology of
sex differences can advance neuro-oncology care and
research.
Sex differences in brain tumor incidence
and outcome
Primary brain tumors
With few exceptions, sex differences are evident in tumor
incidence and mortality throughout the world and regard-
less of race or age (http://globocan.iarc.fr/Pages/fact_sheets_
cancer.aspx). Cancers that affect both males and females in
all tissues and organ systems frequently exhibit male:female
incidence ratios that range from approximately 1.5:1–3:1
(American Cancer Society (http://www.cancer.org/acs/
groups/content/@editorial/documents/document/acspc-0445
52.pdf) and the Cancer Research UK (http://www.
cancerresearchuk.org/cancer-info/cancerstats/incidence/).
Males not only develop more cancers, they frequently have
poorer responses to therapy as measured by event-free and
overall survival [1–10]. Therefore, a closer examination of
sex differences in cancer is likely to reveal differences in
fundamental mechanisms of tumor initiation, tumor pro-
motion, and therapeutic response. Central to this endeavor
will be delineating distinct relationships between sex dif-
ferences and specific oncogenic mechanisms or molecular
subtypes of cancer, as well as between sex differences and
putative cells of origins for given tumor types. Here we
will consider four different brain tumor types to illustrate
how patterns of sex differences might be used to identify
potential molecular and cellular mechanisms through
which sex affects cancer biology.
In adults, gliomas account for the vast majority of pri-
mary parenchymal brain tumors. This heterogeneous group
of neoplasms includes those with features of astrocytes,
oligodendrocytes, and ependymal cells, and ranges from
World Health Organization (WHO) grade I to IV disease.
With few exceptions, gliomas occur more commonly in
males and do so with some restriction to specific oncogenic
mechanisms [11]. Four molecular subtypes of glioblastoma
(GBM) are recognized [12, 13]. TheMesenchymal subtype,
which is characterized by combined loss of neurofibromin
(NF1), PTEN, and TP53 function, exhibits the greatest and
most consistent disparity in male to female rates (2:1) [14].
The Proneural subtype (TP53 mutation, isocitrate dehy-
drogenase (IDH) mutation, platelet-derived growth factor
receptor (PDGFRA) amplification) and Neural subtype
(epidermal growth factor receptor (EGFR) amplification,
TP53 mutation, CDKN2A deletion) also exhibit sex dif-
ferences that approximate those of Mesenchymal subtype
tumors. In contrast, the Classical subtype (EGFR mutation/
amplification, CDKN2A deletion) occurs equally in males
and females. Further distinctions between those oncogenic
events that exhibit differential modulation by sex will be
critical to understanding how sex affects cancer incidence
and outcome.
Disparity in the rates of brain tumor formation in pre-
pubertal boys and girls is particularly instructive with
regard to possible mechanisms by which sex differences
affect cancer. The peak incidence of pediatric brain tumors
occurs in children less than 4 years of age, when circu-
lating sex hormones are at a lifetime nadir [15, 16]. Similar
to what is observed in adult GBM, sex appears to exhibit
molecular subtype-specific effects in pediatric brain can-
cers. This is well illustrated by medulloblastoma,
ependymoma, and pediatric high-grade glioma. Medul-
loblastoma, the most common malignant brain tumor of
childhood, comprises four distinct subtypes based on gene
expression, mutation, and copy number variations [17–20].
The four subtypes are known as the Wnt, the Sonic
Hedgehog and Group 3 and Group 4. The different sub-
types have been hypothesized to originate from discrete
neural progenitor populations that are present during nor-
mal cerebellar development [21–26].
Only Group 3 and Group 4 medulloblastomas exhibit a
2:1 male to female incidence ratio. Both subtypes possess
isochromosome 17q (loss of chromosome 17p with a du-
plication of 17q), and Group 3 tumors also exhibit
amplification of CMYC. Interestingly, among female cases
of Group 3 medulloblastoma, there is frequent loss of an X
chromosome. Groups 3 and 4 medulloblastoma also share
chromatin abnormalities as a consequence of mutations in
KDM6A and EZH2, which result in dysregulation of his-
tone H3 lysine 27 (H3K27) trimethylation [27]. In contrast,
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the other two molecular subtypes of medulloblastoma do
not possess isochromosome 17q exhibit mutational acti-
vation of the Wnt or Sonic hedgehog pathways and genetic
mutations that affect NCor and SWI/SNF chromatin re-
modeling complexes [27]. These subtypes occur with equal
sex distribution.
Similar to medulloblastoma, pediatric ependymoma also
occurs with an overall male:female incidence ratio of 2:1
as a result of a sex differences within specific subtypes of
disease. In a multi-institutional study by Witt et al. [28],
ependymomas from two separate cohorts of patients were
stratified into three groups: supratentorial, posterior fossa,
and spinal and posterior fossa, by consensus hierarchical
clustering of transcriptional profiles. The posterior fossa
(PF) ependymomas were further subdivided into Group A
and Group B tumors. Group A PF ependymoma occurred
more commonly in males with a median age of presenta-
tion of 2.5 years, while Group B PF ependymoma occurred
equally among older males and females (median age of
presentation was 20 years). In addition to sex and age of
presentation differences, Group A and Group B PF
ependymoma also diverge in their apparent oncogenic
mechanisms. Group A PF ependymomas exhibit a methy-
lator phenotype suggesting epigenetic origins of
dysregulation in multiple cancer-related pathways [28, 29].
Group B PF tumors did not possess a methylator signature
and instead were distinguished by alteration in ciliogenesis
and metabolism [28]. Like medulloblastoma, the different
subtypes of ependymoma may derive from different cells
of origin [30, 31].
Epigenetic mechanisms of tumorigenesis are also likely
in pediatric high-grade gliomas where histone mutations
are frequent [32–39]. In deep midline GBM of early
childhood, lysine 27 is often mutated to methionine
(K27M) in histones H3.1 or H3.3. This results in global
changes in H3K27 trimethylation. Importantly, these GBM
also exhibit a male:female incidence of approximately 2:1,
while those GBM that occur in young children without
histone mutation and by other oncogenic mechanisms such
as RB1 mutation [33] do not.
Taken together, the sex effects in medulloblastoma,
ependymoma, and pediatric high-grade glioma suggest that
specific mechanisms of tumorigenesis and particular
populations of progenitor cells may be most sensitive to the
influence of sex. Both ependymoma and high-grade glioma
exhibit the strongest effects of sex in subgroups in which
epigenetic mechanisms appear to drive tumorigenesis.
These observations raise the question of whether epigenetic
mechanisms of brain tumorigenesis may be particularly
sensitive to the effects of sex. Further, both medulloblas-
toma and pediatric high-grade glioma exhibit sex effects in
subsets of disease in which there is dysregulation of histone
H3K27 trimethylation, potentially providing reason to
focus on this particular aspect of epigenetics. As discussed
below, early sex determination is a period of large-scale
epigenetic change as a consequence of the organizing ef-
fects of sex hormones. Finally, in all three tumors, sex
differences are limited to specific subtypes, which could
reflect sex-specific vulnerabilities within particular pro-
genitor populations.
Molecular subtype-specific sex effects can also be ob-
served in brain tumors that do not exhibit sex differences in
incidence. While supratentorial ependymoma occurs with
equal overall frequency in males and females, the Gil-
bertson group recently reported a novel fusion oncogene in
supratentorial ependymoma with a significant male preva-
lence (M/F = 2/1) [40]. Similarly, Warrington et al. [41]
recently reported sex-specific effects of polymorphisms in
adenylate cyclase 8 in individuals with NF1 and glioma,
despite an equal incidence of low-grade glioma in males
and females. These studies indicate that further subgroups
exist within these diseases and raise the possibility that
male and female brain tumor patients may require different
approaches to treatment under certain circumstances.
Secondary brain tumors
Secondary brain tumors or brain metastases can complicate
many cancers, especially those primary diseases involving
the lung, breast, colon, kidney, or skin [42]. The incidence
of secondary brain tumors appears to be on the rise. A
prospective study by Smedby et al. [43] showed the rate
has doubled in Sweden over the past two decades. This
dramatic change in brain metastases is largely attributed to
advancements in primary cancer care, including better
early detection and frontline therapies which lead to longer
initial survival and a greater rate of death from recurrent
and disseminated disease [44]. Excluding sex-specific
cancers like breast cancer, males have significantly higher
rates of brain metastases than females in almost all cancer
types [11, 45].
Brain metastasis is a complicated process involving
epithelial-mesenchymal transition (EMT), evasion of im-
mune surveillance, crossing the blood–brain barrier, and
establishment of tumor growth within the brain parenchy-
ma [46]. During each step, there may be sex-specific
biological differences that contribute to the overall sex
disparity in brain metastasis rates. There have been few
direct analyses of possible sex differences in EMT. In a
lung cancer model, it was observed that periostin expres-
sion, a marker for EMT, was more highly expressed in
biopsies from male patients compared to those from female
patients [47]. Periostin has been demonstrated to enhance
glioblastoma stem cell function [48]. As detailed below,
immune surveillance is profoundly different in males and
females, and a recent study demonstrates that there are sex
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differences in blood–brain barrier permeability in multiple
sclerosis [49].
Meningioma
Meningiomas occur with a striking sex disparity. They are
more than twice as likely to occur in adult females, ages
30–70, and risk factors include radiation exposure, in-
creasing age, and genetic predisposition syndromes such as
Neurofibromatosis type 2 (mutation in the Merlin gene)
and Gorlin syndrome (mutation in the Patched gene) [50].
In addition to the differences in their incidence, male and
female meningiomas differ in their grade: meningiomas in
females are more commonly low grade, while those in
males are more commonly malignant.
A growing body of evidence links meningiomas to
acute (activational) effects of sex steroids. First, menin-
giomas rarely develop in prepubertal children when
circulating sex hormones are low. Second, women develop
meningiomas 2 times more frequently than men; and
third, meningiomas are known to express progesterone
and estrogen receptors [51, 52]. In fact, hormone re-
placement therapy in women has been shown to increase
the risk of meningioma [53]. In addition, there are case
reports of rapid growth of meningiomas during pregnancy,
which then stop growing after delivery [54–58]. Menin-
giomas have not been linked to female oral contraceptive
use, suggesting that either higher or normal variation in
estrogen and progesterone action may be required for tu-
morigenic effects [59, 60].
In addition to potential tumor-promoting effects of
estrogen and/or progesterone, disparities in meningioma
rates may also be the product of protective effects of
testosterone. In men with prostate cancer undergoing an-
drogen deprivation therapy, there is an increased risk of
meningioma growth. Meningioma biopsies express
luteinizing hormone-releasing hormone receptor, and it is
thought that high testosterone levels may be protective
against meningioma [61, 62]. In addition, there are four
case reports in the literature detailing meningioma forma-
tion and growth in male-to-female transsexual patients
undergoing cross-sex hormone therapy [63–66]. The ad-
ministration of estradiol and androgen antagonist
cyprotenone acetate resulted in the development of
meningiomas requiring treatment. Discontinuation of
cyprotenone acetate in one patient was correlated with
tumor regression [66]. The protective effects of androgens
are also suggested by increased meningioma incidence in
females treated with cyprotenone acetate. It is possible that
the apparent exception of meningioma to the pattern of
male predominance in intracranial tumors is related to its
strong link to sex hormone action.
Mechanisms of sex effects in cancer
The mechanisms by which sex can affect cancer rates and
outcome range from the cellular to the organismal level.
For examples, cellular and organismal metabolism and
growth rates differ as a function of sex. Immune function is
profoundly different in males and females, and the dis-
parity in the incidence of cardiovascular disease suggests
vessel function may be fundamentally different. Here we
will review cell intrinsic and non-cell intrinsic mechanisms
by which sex can exert an effect on cancer (Fig. 1).
Cell intrinsic mechanisms
P53
At the core of human cancer cell biology is the inactivation
of RB1 and p53 function [67]. Each of these tumor sup-
pressors plays an indispensible role in maintaining normal
cell number and preservation of genomic stability and
function. Changes in p53 function can have different
consequences in males and females in multiple species.
The first description of sexual dimorphism in the p53
pathway was in mice with complete loss of p53 function.
Initial characterization of these mice suggested that they
underwent normal development but had increased rates of
spontaneous tumor formation [68]. Closer examination of
neural development revealed that nearly 25 % of female
p53-/- embryos developed neural tube defects (NTD) and
died [69]. The sex-specific effect of p53 loss on neural tube
closure has been ascribed to differences in X gene dosage
[70]. In addition, the zinc finger protein, Lyar, has been
shown to function synergistically with p53 loss in pro-
moting NTDs and death of female embryos [71].
Given the importance of p53 function for tumor sup-
pression, it is not surprising that sexual dimorphism in the
p53 pathway could impact on cellular transformation. We
recently demonstrated that upon loss of p53 function, male
and female Nf1-/- astrocytes exhibited significantly dif-
ferent growth rates and clonogenic potential. Male Nf1-/-
; DNp53 astrocytes grew four times faster than female
Nf1-/-; DNp53 astrocytes and exhibited an approximately
ten-fold increase in clonogenic cell frequency [14]. These
sex differences in loss of p53 function contributed to dif-
ferences in transformation and in vivo tumorigenesis.
Although overexpression of p53 ordinarily leads to em-
bryonic lethality in mice, a mouse model with a single allele
of p53 hyperactivation exhibited reduced incidence of
spontaneous tumors [72]. Unexpectedly, gain of p53 func-
tion was also associated with signs of premature aging. In
drosophila, male and female flies exhibited different re-
sponses to stress-induced p53 activation, and upregulation
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of p53 promoted a longer life in male flies, while reducing
lifespan in females [73]. Sex differences in human life span
are evident across the globe, and females are well known to
live longer lives than males. Since cancer risk rises with
age, sexual dimorphism in the p53 pathway may have dif-
ferential impacts on human aging and cancer risk secondary
to it.
RB1
We recently demonstrated that significant sex differences
exist in the regulation of RB1 function in mice. Using a
murine model of glioblastoma in which astrocytes served
as the cell of origin, we showed loss of p53 function
resulted in a remarkable increase in in vitro growth as
well as in vivo tumorigenicity in male, but not female,
astrocytes [14]. We further demonstrated this is due to
sexually dimorphic RB1 activity in the astrocytes, and
when both RB1 and p53 functions were depleted, both
male and female astrocytes showed a similar potential for
forming tumors. This evidence indicates that sexual di-
morphism exists upstream of RB1 function and that when
RB1 is intact, sex differences in its regulation can have
significant effects on malignant transformation. Consistent
with our findings, adult and pediatric high-grade gliomas
with RB1 mutation occur with equal frequency in males
and females ([33] and our unpublished TCGA data ana-
lysis). Moreover, RB1 and CDKN2A loss are mutually
exclusive genetic events in GBM, suggesting equivalent
consequences of their loss of function (our unpublished
TCGA data analysis). CDKN2A loss is a signature event
in Classical GBM, which also occurs with equal fre-
quency in males and females [14].
Similar to p53, Rb functions as a node for integrating
signals regarding genomic stability, proliferation, apopto-
sis, stem cell function, and differentiation. Our recent
findings may have significant implications in both basic
research of cancer biology and clinical practice. For ex-
ample, ongoing clinical trials are evaluating the use of
CDK inhibitors in the treatment of RB1 intact cancers.
CDKs are upstream regulators of RB1 function, and thus it
will be important to determine whether there are sex dif-
ferences in response.
cAMP
Sex differences are also evident in other cell signaling
pathways. We recently demonstrated that both cAMP
synthesis and degradation differ in male and female as-
trocytes, resulting in differences in basal cAMP levels [41].
A relationship between intracellular cAMP levels and hu-
man cancers was established decades ago [74]. A similar
relationship is evident in a number of important mouse
models in which low cAMP levels favor tumor cell growth
and cAMP-elevating drugs like Rolipram exhibit potent
anti-tumor activity [75–78]. Among these models is one of
Fig. 1 Mechanisms underlying
sex differences in cancer:
effects of sex on cancer occur at
the level of cellular
transformation, tumor tissue
organization, and organismal
processes that impact on cancer
occurrence and outcome.
Pictured are processes discussed
in the text. Background to the
cellular processes is a
medulloblastoma cell with the
nucleus in blue and a primary
cilium evident in green
overlying the nucleus.
Background to the tissue
processes is CXCL12
expression (brown) in glioma
tissue. Background to the
organismal processes is a blood
smear with a neutrophil
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Neurofibromatosis type 1 (NF1)-associated optic pathway
glioma [79]. In this model, we were able to alter the
stereotypical pattern of glioma formation through forced
expression of the cAMP-specific phosphodiesterase
PDE4A1 and focal reductions in cAMP levels [75]. These
data indicated that cAMP levels were a determinant of
tumorigenesis in NF1. Based on these results, we per-
formed a human genome-wide association study and found
that polymorphisms in the adenylate cyclase 8 gene were
correlated with glioma risk in NF1 but in a sex-specific
fashion, elevating risk in females and suppressing risk in
males [41]. These data indicate that sex might play a role in
the overall contribution of cAMP to gliomagenesis of NF1
and possibly in other brain tumors. It also raises the
question of whether male and female patients would re-
spond differently to the cAMP-elevating drugs.
Non-cell intrinsic mechanisms
Sex differences in immune function
The immune system plays an essential role in cancer pre-
vention, and harnessing its power is a goal of a number of
current experimental treatments. However, profound dif-
ferences exist in immune function between males and
females, and these may need to be addressed in treatment
protocols. Differences in male and female immune function
are most evident in autoimmune diseases. Multiple scle-
rosis (MS) and rheumatoid arthritis (RA) occur twice as
commonly in females compared to males [80, 81] and
greater than 90 % of all Systemic Lupus Erythematosus
cases are in females [46, 82].
The mechanism(s) underlying these sex differences are
likely to be complex, but include sex hormones acting
through their classic steroid receptors (i.e., estrogen and
androgen receptors) as well as non-canonical receptors
(i.e., GPR30) expressed by immune effector cells [83].
Estrodial (E2), acting through its receptor ER alpha, pro-
motes expansion of antigen-specific CD4 T cells and Th1
cells. These in turn produce interferon—gamma [84]. E2
has also been demonstrated to enhance interferon—gamma
production by natural killer (NK) cells [85]. In contrast,
androgens directly inhibit T-helper cell differentiation and
suppress the adaptive immune response [86]. In addition to
sex hormone actions, X chromosome encoded alleles, in-
cluding several microRNAs, are known to exert direct
effects on immune function [87, 88].
While sex differences in lymphocyte function may
contribute to anti-brain tumor immune activity, it is the
microglia that are the primary effectors of central nervous
system immunity [89]. Long-lived resident microglia
populate the neural tube early in development [90]. They
derive from the macrophage–monocyte lineage, and
through their phagocytic functions and their elaboration of
cytokines, growth factors and chemokines, they play cri-
tical roles in regulating neural stem cell function, cell
number, and synaptogenesis during normal development
[89, 91–93].
Resident microglia as well as infiltrating bone marrow-
derived macrophages/microglia are active in pathological
conditions including brain tumors. Microglia are abundant
in human glioma [94] but their precise roles remain un-
clear. In some cases, pro-tumorigenic roles for microglia
have been observed, such as expansion and migration of
glioma cells in response to microglia-derived signals [95–
97]. In contrast, other studies showed that the activation of
microglia and macrophages decreased tumor growth in
mice, indicating that tumor-associated microglia and
macrophages may have anti-tumor effects [98–100]. In line
with these results, genetic depletion of macrophages in-
creased glioma growth in vivo [101]. Significant sex
differences exist in the numbers and activity of microglia
throughout life [88, 102–104]. It will be interesting to de-
termine whether any of the variability in apparent tumor-
associated roles for microglia is sex dependent.
Astrocytes are also important effectors of central ner-
vous system immune response. Astrocytes have well-
established sexually dimorphic behavior, particularly in the
elaboration of cytokines. Inflammation-associated astro-
cyte production of IL-1b, IL-6, and TNF-a is greater in
male compared to female astrocytes [105]. Each of these
cytokines can stimulate the growth of experimental cancers
and may contribute to sex differences in brain tumor rates.
Sex differences of aging stroma
Context matters: whether a transformed cell eventuates into
a tumor has a great deal to do with the surrounding tissue
microenvironment. Healthy stroma can prevent the pro-
gression of cancer, and tissue disruption can induce
progression. Striking examples of the role of stroma in
tumor formation include the induction of mammary car-
cinomas in mice after implantation of normal epithelial
cells into mutagenized mammary fat pads but not when
mutagenized epithelial cells were implanted into control fat
pads [106], the production of tumors in RSV expressing
chickens only in the setting of inflammation [107], and the
injection of teratocarcinoma cancer into a mouse blastocyst
leading to healthy normal tissues [108].
Tissue-based cancer-suppressive mechanisms may un-
derlie the relegation of most cancers to old age. Aging
stroma is more permissive for cancer progression, and the
properties of aging stroma are in turn often governed by
sex differences. There are both direct and indirect links
between sex, the aging stroma, and cancer. One of the most
profound sex differences in aging stroma exists in the
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differential inflammatory response, as discussed above.
There is an innate, bidirectional interaction between in-
flammatory mediators and sex steroid hormones [109].
Females are less susceptible to hepatocellular carcinoma—
the most common cancer of the liver—which is often
caused by chronic inflammation due to hepatitis viral in-
fection. Colorectal cancer is also more common in men
than women, and the difference is more striking among
premenopausal women and age-matched men.
Another potentially important difference in aging stroma
may be linked to telomere shortening in men [110]. While
it is unclear whether telomere shortening is a causative or
correlative factor in mortality [111], it is uncontroversial
that on average, men have shorter telomeres than women.
Telomere down-regulation is common as we age, and the
rate at which protective telomere chromosome caps are lost
is higher in men. Because critically short telomeres induce
cellular replicative senescence or cell death, by removing
telomerase-driven maintenance, telomere shortening limits
the number of times a cell may divide, and so telomerase
down-regulation may have evolved in response to the in-
creased risk of cell immortalization and cancer that
accompany larger size. So, size dimorphism may be a
cause of increased telomerase shortening in men. Large
size means more cell divisions as we age, and thus po-
tentially a greater risk of cell immortalization and cancer
risk. However, estrogen directly activates a promoter of
telomerase, and so may also indirectly affect differential
rates of shortening as we age [112].
Sex chromosome haploidy may also differentially affect
aging stroma and thus lifespan; this has been called the
‘‘unprotected X chromosome’’ theory. Males are the
heterogametic sex and are vulnerable to a variety of
X-linked diseases, where only a single loss of function
mutation is needed for diseases such as hemophilia, Lesch
Nyhan syndrome, and muscular dystrophy. Females are
mosaics, with stochastic inactivation in each cell of one or
the other X chromosome; this mosaicism is arguably pro-
tective against disease. As females develop, there is a skew
in the ratio of X-inactivation, presumably due to the greater
fitness of one or another chromosome.
Cumulative damage to cells due to oxidative stress may
also differentially affect the sexes, in part due to sex dif-
ferences in size, or possibly due to hormone-mediated
production of ROS (reactive oxygen species). Estrogen
reduces the production of ROS and is a potent antioxidant
and regulator of antioxidant genes; conversely, testosterone
has no antioxidant properties [113, 114]. This has been
called the ‘‘oxidative handicap hypothesis,’’ or the
‘‘mother’s curse,’’ given the role of mitochondrial DNA in
oxidation. According to Tower [115], ‘‘mitochondrial
malfunction should contribute to the aging phenotype, and
perhaps do so in males more than females,’’ on the theory
that mutations that are substantially harmful to males can
accumulate in mitochondrial genomes if they are only
slightly deleterious, neutral, or beneficial to females [116–
120]. There is some experimental evidence that variance in
naturally occurring mitochondrial haplotypes in
Drosophila melanogaster affected lifespan and mortality
rates in males but not in females, which is consistent with
the idea of mutation load in mitochondrial genome af-
fecting male aging [116]. However, a recent review argues
that the experimental evidence is tenuous with respect to
this hypothesis [121].
These differences in aging stroma are likely affected by
a variety of proximate and more remote causal processes.
As discussed below, there may be an evolutionary expla-
nation. Differential sex-specific fitness—e.g., with respect
to selection for various traits that affect fertility—could
lead to antagonistic coevolution of traits that affect both
sexually selected traits and cancer risk. Sexual selection
could also lead to differential epigenetic effects. Parental
imprinting can be sex specific, and may play a critical role
in development and aging. Whether directly or indirectly,
sex differences can lead to differences in how diet and
environmental compounds affect cancer risk in males
versus females.
Vascular function
An additional significant and potentially cancer relevant
sex difference is the effects of sex on vascular function.
Cardiovascular disease occurs with greater frequency in
men and post-menopausal women than in premenopausal
women [122]. The mechanistic basis for these well-estab-
lished observations remains unclear and may include sex
differences in response to early environmental stressors as
well as acute vascular actions of sex hormones [123]. Po-
tential hormone-dependent mechanisms include estrogen-
stimulated vasodilatory effects of nitric oxide and prosta-
cyclins, as well as anti-inflammatory and antioxidant
effects of estrogen [124]. Given these demonstrated effects
of estrogen, it is unclear why estrogen replacement therapy
for post-menopausal women has been associated with ad-
verse vascular events [125], and estrogen therapy for male
to female transsexuals has been causally related to their
increased cardiovascular disease [126]. Further, testos-
terone treatment of female to male transsexuals is not
correlated with a change in cardiovascular disease fre-
quency, and testosterone antagonist therapy in men with
prostate cancer increases cardiovascular adverse events.
Thus, there appear to be cardiovascular protective effects
of testosterone [127]. While these observations indicate an
incomplete understanding of the mechanisms by which sex
affects cardiovascular function, they should stimulate
consideration of whether sex differences in vascular
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function might extend to sex differences in tumor-associ-
ated angiogenesis as well as sex differences in endothelial
cell effects on brain tumor stem cells. The perivascular
space is an essential brain tumor stem cell niche. We, and
others, have demonstrated that endothelial cell–glioblas-
toma stem cell crosstalk plays an essential role in inducing
and maintaining the glioblastoma stem cell state [128].
This is critically important as perivascular niche function
stimulates tumor growth, resistance to therapy and recur-
rence after treatment, and is known to involve nitric oxide
metabolism [129].
Developmental origins of sex differences
The state of human health and disease is determined
throughout life by genetics, epigenetics, environmental ex-
posures, and aging-associated degradation of genomic,
cellular, and tissue function. At each stage, from conception
to death, males and females differ as a consequence of their
chromosome complement, epigenetics, and hormone ac-
tions. Each of these component mechanisms has been
shaped by evolution to create and maintain phenotypic dif-
ferences between the sexes, a process collectively referred to
as sexual determination [130]. While overt sex differences
that emerge at each stage of normal development can range
from subtle to profound, additional and significant under-
lying sex differences have been revealed under suboptimal
growth conditions or frank pathological states. Differences
in adaptations to in utero stressors may have particular
relevance to this discussion in light of the ever-expanding
body of data to support Developmental Origins of Health
and Disease [131]. How normal sex determination and
sexually differentiated function affects cancer risk is not
understood. It is important to consider, however, as cancer
occurs more commonly in males, and therefore sex differ-
ences in genetics, epigenetics, and hormone actions must
play specific mechanistic roles in malignant transformation
and cancer progression. Here we will review the mechan-
isms of sex determination and highlight how the resultant
sexual dimorphism could impact on oncogenesis and sex
differences in cancer rates. Oncogenesis involves among
other things, alterations in epigenetics, gene expression,
metabolism, immune function, and angiogenesis. Each of
these areas is a target of sex determination, and therefore we
will discuss each at different major epochs of development
including pre-implantation, post-implantation, puberty, and
adulthood (Fig. 2).
Pre-implantation
The pre-implantation stage of development provides a
unique window on the distinct biologies of male and
female sex chromosome complements and their effects on
gene expression, metabolism and growth. During the pe-
riod preceding X-inactivation and formation of the
placenta, embryo biology is dictated by the differences in
chromosome complement and direct sex chromosome ef-
fects on genome-wide epigenetics, gene expression, and
metabolism. Decades of observations have demonstrated
that under most conditions, male embryos grow faster than
female embryos [132–134]. This is true in multiple
eutherian species, including humans, as well as in birds
[135]. At this earliest stage of development, differences in
growth rate may be determined most potently by differ-
ences in glucose and amino acid metabolism,
mitochondrial complement, and in rates of apoptosis [133,
134, 136–140]. Differences in metabolism are driven most
directly by differences in gene dosage of X encoded
metabolic regulators whose expression can be further
modified by imprinting. Sex differences in expression of
Fig. 2 Developmental origins of sex differences: At all stages of life
from fertilization until death, sex differences arise through direct
effects of differences in sex chromosome complement, and the
organizational and activational effects of sex hormones. Pictured are
stages of development discussed in the text
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the X chromosome encoded and cancer metabolism-related
genes glucose-6-phosphate dehydrogenase (G6PD) and
O-Linked N-acetylglucosamine (GlcNAc) transferase
(OGT), differ at both the mRNA and protein level in the
blastocysts of multiple species and are correlated with
measurable differences in glucose metabolism [141–143].
During the first week post-fertilization, the embryo shifts
from using pyruvate to glucose as an energy source [133].
During this time, pyruvate uptake by early male embryos
exceeds that of females, and direct measurements of total
glucose metabolism and pentose phosphate shunt activity
indicate that male embryos metabolize greater quantities of
glucose but pentose phosphate shunt activity is four-fold
greater in female embryos [136, 144]. In addition, mea-
sures of glutamine metabolism indicate that Kreb cycle
activity is also greater in male embryos, possibly consistent
with their greater mitochondrial DNA content [136]. Dif-
ferences in metabolism are correlated with measurable
differences in the speed of embryo growth and develop-
ment [132, 145, 146]. The relatedness of differences in
glucose metabolism to cancer growth is an enormous area
of active research [147]. Whether sex differences in
metabolism are evident in brain tumors and how differ-
ences in metabolism might affect the thresholds for
transformation in brain tumors has yet to be addressed but
will undoubtedly be an important application of the biology
of sex differences in the development of metabolic ap-
proaches to cancer care.
Prior to X-inactivation sex differences in blastocyst
epigenetics are evident. A component of sex-specific epi-
genetics is attributable to O-Linked N-acetylglucosamine
(GlcNAc) transferase (OGT), which is more highly ex-
pressed in female embryos [151]. OGT provides a link
between metabolism and histone H2B O-GlcNAcylation
[152] and has recently been implicated in the aberrant
epigenetics of cancer [153]. In addition, KDM6A (UTX) is
an X encoded lysine demethylase and an essential regulator
of histone H3 lysine K27 (H3K27) methylation [154]. The
status of H3K27 trimethylation is critical for normal de-
velopment and differentiated function. The importance of
appropriate regulation of H327 methylation is underscored
by the frequent mutation of H3K27 to methionine in pe-
diatric glioblastoma [32–39]. In this regard, H3K27
demethylase activity may differ in male and female cells.
UTX escapes X inactivation [155] and its Y chromosome
paralog UTY does not possess the same degree of catalytic
activity [156]. UTX has already been suggested to play a
sex-specific tumor suppressor role in T cell acute lym-
phoblastic leukemia [157].
The most singular difference between male and female
epigenetics at this stage is the random inactivation of either
the maternally or paternally acquired X chromosome [158,
159]. This uniquely female event occurs in stages in
progenitor cells and is perpetuated in all subsequent
daughter cells. It results in the transcriptional silencing of
most alleles on one of the X chromosomes and involves the
coating of the inactivated regions by the non-coding RNA
Xist, deacetylation of associated histones, and methylation
of X chromosome DNA [160]. The extent of X inactivation
is normally variable and consequently there is incomplete
silencing of X encoded alleles [161]. Among the genes that
escape inactivation are those with paralogs in the pseudo
autosomal region (PAR) of the Y chromosome. This
component of X inactivation preserves equal gene dosage
in males and females, except in cases like UTX where the
Y paralog does not possess equivalent activity. Escape
from inactivation is not limited to PAR paralogs. Conse-
quently, mosaicism occurs within female tissues on the
basis of random X inactivation and variable X gene dosage
resulting in expressed heterozygosity for some maternal
and paternal alleles. This is in contrast to maternal-only X
chromosome gene expression in male tissues. How variable
X chromosome inactivation and X mosaicism relates to sex
differences in health and disease including cancer predis-
position is not known. The field of induced pluripotent
stem cells has revealed significant relationships between X
reactivation, pluripotency, and viability [162]. This is
relevant to cancer, as malignant transformation of differ-
entiated cells requires the re-acquisition of a pluripotent-
like state in the subset of cells with tumor-initiating ca-
pacity. Thus, transformation may require fundamentally
different processes for male and female cells. The possi-
bility is supported by the oncogenic effect of blocking Xist
expression in mice [163].
Post-implantation
Post-implantation in utero growth and development is de-
termined by maternal conditions, placental function, post
X-inactivation differences in chromosome complement,
and testosterone action. The placenta is derived from fetal
tissues and is thus XX or XY. It is the primary regulator of
in utero homeostasis for the fetus, and placental responses
to maternal stress reveal sex differences in epigenetics,
vascular, immune, and hormonal function. In male pla-
centae, microvessel dilatation in the face of maternal
hypertension preserves placental perfusion, size, and fetal
growth rate [166, 167]. In response to maternal nutrient
deprivation, IGF2 synthesis and secretion become elevated
in male placentae and male fetal growth is again preserved
compared to female fetal growth [168]. The absence of
these adaptations in female placentae is associated with
reduction and retardations in in utero growth but increased
survival. Notable among the female placental adaptations
to in utero stress is the upregulation of immune system
genes [169]. In response to maternal asthma, multiple
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cytokine genes are up-regulated in female placentae. No
comparable response is observed in male placentae and
evidence for higher rates of intrauterine infection in pre-
term male deliveries are observed [170]. OGT activity (see
above) has recently been identified as one of the mediators
of sex-specific placental epigenetic responses to in utero
stress [171].
Sex-specific placental and fetal epigenetic responses to
in utero stressors may be widespread [164]. In a fascinating
study of pregnant Gambian women, micronutrient supple-
mentation resulted in different post-natal effects on the
male and female methylome [148]. These differences in-
volved non-overlapping autosomal loci with enrichment for
different functional categories. In females, methylation
changes involved components of immune and non-immune
anti-infective action. In contrast, none of these genes were
affected by supplementation in males. Instead, target genes
in males were involved in growth and development. Several
imprinted genes were also differentially affected by mi-
cronutrient supplementation. Notable among these was
GNAS, the stimulatory alpha subunit of heterotrimeric G
proteins and a critical regulator of cAMP levels. We, and
others, have shown that cAMP levels regulate normal and
neoplastic growth in the nervous system [41, 75–78].
Moreover, we have recently shown that polymorphisms in
cAMP regulators are associated with sex-specific effects on
brain tumor risk in individuals with Neurofibromatosis type
1 [41]. Multiple other examples of sex-specific epigenetic
responses to in utero conditions have been published, in-
cluding the effect of folate on methylation in genes involved
in gut development [149], and the effect of placental in-
sufficiency on methylation of the HSD2 gene [150].
Together these observations raise the possibility that sex
differences in epigenetics allow males and females to pre-
serve different aspects of homeostasis. In this regard, it is
interesting to note that male adaptations to multiple forms
of in utero stress preserve their growth rate at the expense of
survival [165]. The female adaptation results in a reduction
in growth rate and upregulation of immune response genes.
It is interesting to consider how sex differences in baseline
and stress-induced epigenetics might relate to sex differ-
ences in thresholds for malignant transformation. The
oncogenic effects of abnormal histone modification and
DNA methylation, together with the anti-tumor effects of
histone deacetylase and DNA methyltransferase inhibitors,
highlight the critical role that epigenetic regulation plays in
cancer and therapeutic response. If male epigenomes are
poised to preserve growth over function, while female
epigenomes are poised to preserve function over growth, are
males more susceptible to an uncontrolled growth response
to genotoxic stressors than females?
After the formation of the testes, in utero sex differences
are increased through testosterone action. Even transient
exposure of fetal tissues to testosterone was shown more
than 50 years ago to have permanent effects on phenotype
and behavior [172]. These observations inspired the con-
cept of organizational effects of sex hormones as distinct
from their acute actions. In the brain, organizational effects
of testosterone, primarily acting as estradiol through aro-
matase-dependent conversion, result in sex differences in
astrocyte and neuron numbers, the size of the resident
microglial population, as well as synaptic density and
function [173]. Other important macroscopic sex differ-
ences in brain development include the kinetics of brain
growth and myelination, and ultimate brain size and degree
of myelination [174, 175]. The precise mechanisms that
contribute to the organizational effects of sex hormones on
brain size and function remain to be fully elucidated. They
involve changes at the molecular level involving histone
modification and DNA methylation, as well as at the level
of differences in cellular composition and tissue structure.
Sex differences in the kinetics and magnitude of microglial
accumulation have been hypothesized to play a role in the
differing stage of life vulnerabilities of males and females
to mental illness and other neurological disease that exhibit
significant sex differences [102]. As discussed above, mi-
croglia accumulate in brain tumors and have been shown to
exert both pro- and anti-tumor effects. Whether sex dif-
ferences in microglial accumulation are evident in brain
tumors and what, if any, effect sex differences in microglia
numbers and function may have on brain tumor incidence
and outcome has yet to be directly addressed.
Using a model of glioblastoma, we explored the con-
sequences of in utero sex determination on malignant
transformation. We found that in response to progressive
perturbation of growth regulation through step-wise loss of
neurofibromin and p53 function and activation of the EGF
receptor pathway, male murine astrocytes exhibited ac-
celerated growth, expansion of a clonogenic stem-like cell
fraction, in vitro soft colony formation, and in vivo tu-
morigenesis [14]. Female astrocytes did not exhibit similar
growth and neoplastic changes. Resistance and suscepti-
bility to transformation were related to differences in Rb
regulation and again suggest that males and females are
poised to respond to perturbations that threaten normal
growth in fundamentally different ways that may have
great relevance to cancer risk and response to therapeutics.
The relative contributions of sex chromosome complement,
and the organizational effects of sex hormones to sexual
dimorphism in Rb regulation, remain to be measured.
Puberty and beyond
Among the profound consequences of in utero sex deter-
mination are the organization of tissues to respond to signals
at the onset of puberty, which manifests in functional
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gonads, additional organizational and acute activational
effects of sex hormones, and secondary sex characteristics.
Post-puberty differences in estrogen and testosterone levels
exert potent control over tissue structure and function and
organismal behavior in health and disease [16]. The impact
of sex hormones on human disease is indicated by numerous
correlates between disease incidence and changing levels of
sex hormones, as well as in experimental settings when
hormone action is manipulated by gonadectomy or treat-
ment with exogenous steroids. A series of studies have
examined estrogen effects in experimental models of
medulloblastoma. Primary patient tissues and cell lines, as
well as genetically engineered mouse models of medul-
loblastoma demonstrate expression of estrogen receptor b
isoforms [176, 177]. Estrogen receptor activation promotes
medulloblastoma growth in experimental models [178]
suggesting a potential benefit for estrogen receptor blockade
in medulloblastoma treatment [176].
Pregnancy and cancer
Cancer incidence increases slightly following pregnancy,
and higher rates of incidence are found in women who
delay first pregnancy to late in life, suggesting hormone-
mediated effects on cancer risk [179]. However, acute
hormone actions may not be the only way in which preg-
nancy affects cancer incidence and progression. Recently,
the potential for fetal microchimerism, in which fetal cells
persist post-partum in maternal tissues, to play a unique
role in women’s health and disease has been described
[180]. Fetal microchimerism appears to have several pro-
tective and potentially deleterious effects including
promotion of wound healing but instigation of autoimmune
disease. Several provocative findings suggest that fetal
microchimerism may play either a protective or a pro-tu-
morigenic role in some women’s cancers [181–185]. How
fetal microchimerism might affect brain tumor biology and
outcome has yet to be addressed.
Evolutionary basis for sex differences
Evolutionary mechanisms related to sex differences
in growth and cancer
Many sex differences that play a role in cancer risk may be
by-products of evolutionary processes. Natural selection
does not result in fully optimized traits for all individuals at
all times. Instead, the relative fitness, or adaptive advan-
tage, a trait confers on the organism is always a
compromise or trade-off between competing fitness inter-
ests. There are two general classes of such trade-offs:
antagonistic pleiotropy and antagonistic coevolution.
Antagonistic pleiotropy occurs when a genetic variant
confers a fitness advantage for an organism in one respect
(perhaps with respect to reproductive success), but may be
disadvantageous in another respect (perhaps by raising
cancer risk and thus reducing life span); CAG repeats in the
androgen receptor in men may be a vivid case of this,
discussed below. Antagonistic coevolution is genetically
based conflict between entities with competing fitness in-
terests; such conflicts can occur between hosts and
parasites, mothers and fetuses, or, males and females, in
which case it is called ‘‘sexual conflict.’’ Sexual conflict
may lead to the evolution of divergent genetic and epige-
netic systems involved in immune response, metabolism,
growth, and aging. The genes involved in such systems
may promote differential cancer risk as a secondary effect
[186]. Here we will review evolutionary mechanisms that
may contribute to sex differences in cancer risk. In par-
ticular, we hypothesize that intralocus sexual conflict
(displacement of the sexes from phenotypic optima as a
result of sex-specific selection on shared traits regulated by
Fig. 3 Evolutionary processes underlying sex differences. A frame-
work for organizing evolutionary processes that can impact on cancer
risk with an emphasis on those that could underlie sex differences in
cancer risk. The trunk and branches illustrate mechanistic relation-
ships. No phylogenetic relationships are inferred
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shared genetic machinery) may play a significant role in
differential cancer risk. Sex differences in growth regula-
tion may establish different thresholds for malignant
transformation in males and females and thus account for
the differences in their cancer rates (Fig. 3). Understanding
the selected mechanisms governing such thresholds will be
essential, in our view, to more effective cancer care.
Antagonistic pleiotropy
The antagonistic pleiotropy model of cancer risk suggests
that alleles with late-acting deleterious effects are main-
tained in the population by active selection because these
same alleles have benefits during early developmental and/
or reproductive stages. Thus, for instance, increased height
or weight in males might increase one’s chances of com-
peting successfully for a mate, but might also in turn raise
one’s risk of cancer later in life. Large size is associated
with greater cancer risk, particularly in fast-growing tissues
such as bone and brain. Recent evidence suggests this may
be related to the strong correlation between lifetime risk of
cancer and the number of divisions within self-renewing
cell populations [187]. Interestingly, pediatric cancers most
commonly involve bone marrow, bone, and brain [186],
and are significantly more common in males than females
[15, 188]. Thus, large size and rapid development in males
may increase their fitness but also increase their cancer risk
[189]. Summers and Crespi argue that the CAG region of
the androgen receptor is a locus of antagonistic pleiotropy.
Short repeats are associated with increased transactivation
of the androgen receptor and increased fertility, but also
increased risk of prostate cancer and more aggressive
forms of disease [190]. In contrast, increased CAG repeat
length is associated with hypo-androgenicity, low rates of
spermatogenesis, and reduced male-specific traits.
There does not appear to be similar selective pressure
for large size in females. In fact, there are multiple lines of
evidence to indicate that growth optima in males and fe-
males are quite different. Consider paternal and maternal
imprinting effects on the pro-growth gene IGF2 and the
growth suppressive gene H19. Paternal imprinting of H19
blocks expression of the paternally derived allele, while
maternal imprinting of IGF2 blocks expression of the
maternally derived allele. This may be a case where se-
lective pressures to protect the differential growth optima
create different vulnerabilities to genetic events that alter
growth regulation. Males may be more vulnerable to loss of
tumor suppressor or gain of oncogene function because this
moves their growth regulation towards their growth opti-
ma. In contrast, females may be more resistant to the same
cancer-initiating events, because such events displace them
from their optima, and trigger counter regulatory
homeostatic mechanisms. Hypotheses like these can be
experimentally addressed in model systems like the one we
have used to explore sex differences in thresholds for
transformation upon loss of p53 and Rb function [14]. This
may be a vivid example of intralocus sexual conflict (de-
scribed above), mediated by imprinting, though likely also
affected by differential regulatory pathways of gene ex-
pression in males and females.
Many genes associated with cancer also play important
functional roles in other contexts, such as in angiogenesis,
placentation, spermatogenesis, and control of tissue dif-
ferentiation and development. Thus, the maintenance of
these genes may be simply due to other positive effects at
other stages in life history. It is possible that the differential
prevalence, mortality, and progression of cancer in males
versus females are due to antagonistic pleiotropy, i.e., traits
selected to enhance male or female fitness (higher growth
rates and larger size, or early menses) that coincidentally
increase cancer risk later in life, or, antagonistic coevolu-
tion, such as the case of differential regulation of growth
optima, described above.
Sexual selection
Sexual conflict is expected because divergent reproductive
strategies of the sexes lead to different selection pressures
on shared traits. Sexual conflict has a variety of potential
impacts, such as the evolution of displays that reduce
survival. This section will focus on how sexual selection
could drive cancer risk. Sex-specific optimization of re-
productive strategies could result in different life spans and
aging rates, and could cause sexually antagonistic selection
on shared genetic architecture.
Why are sex-specific optima expected to be different?
According to Adler et al. [191], the sexes have different
‘‘opportunity landscapes,’’ where the sex that competes
more strongly for access to mates tends to pursue a ‘‘live
fast, die young’’ strategy, sacrificing longevity for repro-
ductive opportunity. Thus, males are predicted to invest
more in traits that increase reproductive opportunity, which
may in turn sacrifice longevity. Female reproduction is
generally resource limited, so females compete for re-
sources, not males.
Not all sexual conflict is due to competition for mates,
however. Sexual conflict can occur any time that there are
divergent optima for the sexes, either because of different
basic biology (e.g., haploidy, maternal-only inheritance of
mitochondrial DNA), physiology, or reproductive ma-
chinery. Of course, sex antagonism can result from natural
as well as sexual selection. For example, males and females
might be selected to have different body sizes for eco-
logical reasons.
Crespi and Summers have argued that similar an-
tagonistic coevolution may be driving selection on genes
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associated with cancer in human populations [186]. Male–
female conflict may generate evolutionary disequilibrium
in hormonal regulation, especially involving testosterone
and estrogen in their effects on reproductive tissues such as
prostate, testis, ovary, and breast [192–195] while intra-
sexual conflict, such as male–male competition, could lead
to selection of growth factor genes such as IGF1 and IGF2
[196] that fuel the growth of tumors [197]. Further, con-
flicts of genomic imprinting, between paternal and
maternal genes, often involve enhancement or suppression
of cell growth [186, 198, 199].
There are a variety of indirect sources of evidence in
support of intra- and interlocus sexual conflict in humans.
Several cancer genes, involving regulation of hormones,
sexual development, fitness, growth, and development,
have been shown to be subject to positive selection [194,
195].
Intralocus sexual conflict is expected in species with
intense sexual selection on one particular sex. Species with
divergent reproductive strategies are likely to exhibit
highly sex-specific patterns of selection on longevity and
aging. In species with intense male–male competition,
male fitness may depend on large body size, and males may
be selected for high investment in survival until critical
body size is obtained. It is likely that in the evolutionary
past, selection optimized different growth optima in males
and females. These differential growth optima and
homeostatic mechanisms to preserve these optima may
play a significant role in differential cancer risk. Under-
standing these mechanisms, and their evolutionary role,
may be of great value in sex-specific targeted interventions
on cancer—whether in the service of screening and pre-
vention, or treatment.
Integrating the biology of sex differences into lab-
based and clinical investigations
Accounting for the complexities of sex effects on human
health and disease requires an integrative approach. In the
laboratory, molecular mechanisms may need to be
evaluated in both male and female cell models before their
true relevance to human disease can be appreciated, and
preclinical studies should be conducted in both male and
female animals before moving on to clinical trials. The
increased size and cost of experiments and the lack of fa-
miliarity with helpful model systems, experimental
paradigms, necessary controls, and potential pitfalls, all
conspire to make the prospect of exploring sex differences
unattractive. Here we will review several laboratory and
clinical investigations that highlight important experimen-
tal paradigms in sex effect research. Without routine
assessment of whether sex matters it will not be possible to
completely understand brain tumors and other diseases and
to fully realize the value of personalized approaches to
medical care.
Laboratory investigations
Glioblastoma research provides a vivid illustration of how
important observations regarding sex differences in disease
can be overlooked in laboratory and clinical investigations.
It has been consistently noted that more males are affected
by glioblastoma than females in clinical studies since the
earliest publications of treatment responses [200]. More-
over, shorter event-free survival in males has been
repeatedly noted [188]. Despite this common knowledge
about these key differences between males and females,
there has been no coordinated effort in the clinical arena to
prospectively determine whether treatment approaches
should be modified for males and females. In the laboratory
setting, there have been a small number of relevant and
important studies. Reilly and colleagues, using a mouse
model of astrocytoma involving concurrent germline
heterozygous loss of neurofibromin (Nf1) and p53 tumor
suppressor function, demonstrated a male prevalence in
glioma formation [201–203]. The sex disparity in glioma-
genesis was strain specific and Bl/6 mice appeared to be
more susceptible to tumor formation than the 129S4/SvJae
line. In addition, the sex difference in glioma rates was
dependent on the parent origin of the genetic mutations.
We also found that combined loss of Nf1 and p53 function
in differentiated astrocytes had a male predominant effect
on transformation and tumorigenicity [14]. However, when
combined loss of Nf1 and p53 was engineered in neural
stem cells, a high rate of tumor formation was observed
without sex differences [204]. Together these observations
suggest that the magnitude of sex effects may vary as a
function of strain and tumor cell of origin/lineage effects.
In our model of Mesenchymal GBM, the effect of sex on
transformation was evident in the absence of sex hormones,
and thus independent of their acute activational effects.
In vivo tumorigenesis was also unaffected by whether male
or female implants were made into male or female mice. In
contrast, in a U87 xenograft model, female recipient nude
rats survived longer than their male counterparts [205].
Estrogen receptor beta activation has been shown to inhibit
the growth of human GBM cells [206]. These findings may
indicate that there is a tumor suppressive function of
estrogen.
Ruling out acute activational effects of sex hormones on
transformation and tumorigenesis in our model means that
these sex differences must arise either as a result of the
differences in chromosome complement or the organiza-
tional effects of sex hormones. The four core genotypes
mouse model can distinguish between prenatal effects of
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sex chromosome complement and sex hormones [207]. In
these mice, the testes determining gene Sry has been
transferred from the Y chromosome to an autosome on a
Bl6 background. Thus, four genotypes are possible:
XXSry-, XXSry?, XYSry-, XYSry?, resulting in XX/gonadal
females, XX/gonadal males, XY/gondal females, XY/
gonadal males, respectively. Post-natal gonadectomy with
or without hormone replacement/substitution can delineate
additional organizational effects as well as acute activa-
tional effects of sex hormones [208]. Additional genetic
models are available to manipulate expression of X alleles
that escape X inactivation [209, 210] or Y chromosome
gene expression with consomic Y strains [211].
Sex differences in genomic studies
Detecting sex differences in polymorphic risks, mutational
frequencies, or epigenetic landscapes requires analyzing
male and female specimens separately. We recently
demonstrated the value of this approach in identifying sex-
specific modifiers of glioma risk in individuals with neu-
rofibromatosis type 1 [41]. Our studies confirmed that the
cAMP pathway was an important modifier of gliomage-
nesis in humans and revealed for the first time that cAMP
may have a sex-specific effect on glioma. Minor allele
variants in adenylate cyclase 8 (AC8) increased the risk for
glioma in female patients but decreased risk in male pa-
tients. These data indicate that important differences in
oncogenic mechanisms between males and females may be
overlooked when specimens are analyzed together.
Sex-specific effects of polymorphisms are not limited to
AC8. A single nucleotide polymorphism (SNP) in the
MDM2 promoter (SNP309: rs2279744) also exhibits sex-
specific effects on cancer rates [212]. MDM2 is a negative
regulator of p53 function. It is frequently amplified in
human cancers resulting in loss of p53 function. Two al-
leles are described for SNP 309: the GG and the GT
genotypes. The GG allele is associated with increased
MDM2 protein levels and reduced p53 function [212]. The
GG allele has been associated with early disease onset in
various cancers. For instance, the SNP309 has been shown
to be associated with accelerated formation of melanoma
and colon cancer only in women, [213, 214] and even as-
sociated with the early onset of pediatric acute
lymphoblastic leukemia (ALL) in girls (Median age of
diagnosis: girls 36 months versus boys 60 months). [212].
The GG genotype of the MDM2 promoter may increase the
binding affinity of the transcription factor Sp1. Interest-
ingly, Sp1 is a well-characterized co-transactivator of
steroid receptors such as estrogen receptor and estrogen
receptor may thereby modify the influence of SNP309 on
MDM2 function in a sex-dependent fashion [214]. How
sexual dimorphism at the level of MDM2 transcription
might interact with sexual dimorphism at other levels of the
p53 pathway remains to be determined.
Future directions
Ultimately the elucidation of sex differences in cancer in-
cidence and therapeutic response will mandate adaptation
of current cancer screening and treatment approaches for
sex-specific application. Laboratory-based investigations
will need to consider sex differences from the cellular to
the organismal level and preclinical studies should be done
in male and female animal models. Cancer screening pro-
grams will need to stratify risk based on sex-specific effects
of polymorphisms and mutations. Prevention programs will
need to consider sex differences in the molecular
mechanisms of cancer as well as social and behavioral
influences on exposures like tobacco, the sun, or industrial
chemicals. Finally, treatment may need to be tailored to
male and female patients based on disparate molecular
oncogenic mechanisms, different vulnerabilities to specific
toxicities, as well as differences in how their epigenomes
are poised to respond to the genotoxic, physical, psycho-
logical, and social stresses of cancer treatment.
Acknowledgments The authors would like to thank Drs. Michael
Weisberg and David Wilson for critical reading of the manuscript.
Work in the Rubin lab is supported by NIH R01 CA136573 (JBR).
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted
use, distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were
made.
References
1. Ashley DJ (1969) A male-female differential in tumour inci-
dence. Br J Cancer 23:21–25
2. Cook MB, McGlynn KA, Devesa SS, Freedman ND, Anderson
WF (2011) Sex disparities in cancer mortality and survival.
Cancer Epidemiol Biomark Prevent a publication of the Amer-
ican Association for Cancer Research, cosponsored by the
American Society of Preventive Oncology 20: 1629–1637
3. Devarahally SR, Severson RK, Chuba P, Thomas R, Bhambhani
K, Hamre MR (2003) Second malignant neoplasms after pri-
mary central nervous system malignancies of childhood and
adolescence. Pediatr Hematol Oncol 20:617–625
4. Eden OB, Harrison G, Richards S, Lilleyman JS, Bailey CC,
Chessells JM et al (2000) Long-term follow-up of the United
Kingdom Medical Research Council protocols for childhood
acute lymphoblastic leukaemia, 1980–1997. Medical Research
Council Childhood Leukaemia Working Party. Leukemia
14:2307–2320
5. Molife R, Lorigan P, MacNeil S (2001) Gender and survival in
malignant tumours. Cancer Treat Rev 27:201–209
3336 T. Sun et al.
123
6. Pearce MS, Parker L (2001) Childhood cancer registrations in
the developing world: still more boys than girls. Int J Cancer J
Int du Cancer 91:402–406
7. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T
et al (2012) Cancer treatment and survivorship statistics, 2012.
CA Cancer J Clin 62:220–241
8. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics,
2012. CA Cancer J Clin 62:10–29
9. Curran EK, Sainani KL, Le GM, Propp JM, Fisher PG (2009)
Gender affects survival for medulloblastoma only in older
children and adults: a study from the Surveillance Epidemiology
and End Results Registry. Pediatr Blood Cancer 52:60–64
10. Weil MD, Lamborn K, Edwards MS, Wara WM (1998) Influ-
ence of a child’s sex on medulloblastoma outcome. JAMA
279:1474–1476
11. Sun T, Warrington NM, Rubin JB (2012) Why does Jack, and
not Jill, break his crown? Sex disparity in brain tumors. Biol Sex
Differ 3:3
12. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu
TD et al (2006) Molecular subclasses of high-grade glioma
predict prognosis, delineate a pattern of disease progression, and
resemble stages in neurogenesis. Cancer Cell 9:157–173
13. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilker-
son MD et al (2010) Integrated genomic analysis identifies
clinically relevant subtypes of glioblastoma characterized by
abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell
17:98–110
14. Sun T, Warrington NM, Luo J, Brooks MD, Dahiya S, Snyder
SC et al. (2014) Sexually dimorphic RB inactivation underlies
mesenchymal glioblastoma prevalence in males. J Clin Invest
15. SEER Cancer Statistics Review, 1975–2011 [Internet]. National
Cancer Institute. 2013. Available from: http://seer.cancer.gov/
csr/1975_2011/
16. Ober C, Loisel DA, Gilad Y (2008) Sex-specific genetic archi-
tecture of human disease. Nat Rev Genet 9:911–922
17. Cho YJ, Tsherniak A, Tamayo P, Santagata S, Ligon A, Greu-
lich H et al (2011) Integrative genomic analysis of
medulloblastoma identifies a molecular subgroup that drives
poor clinical outcome. J Clin Oncol 29:1424–1430
18. Kool M, Korshunov A, Remke M, Jones DT, Schlanstein M,
Northcott PA et al (2012) Molecular subgroups of medul-
loblastoma: an international meta-analysis of transcriptome,
genetic aberrations, and clinical data of WNT, SHH, Group 3,
and Group 4 medulloblastomas. Acta Neuropathol 123:473–484
19. Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG,
Mack S et al (2010) Medulloblastoma comprises four distinct
molecular variants. J Clin Oncol 29:1408–1414
20. Taylor MD, Northcott PA, Korshunov A, Remke M, Cho YJ,
Clifford SC et al (2012) Molecular subgroups of medulloblas-
toma: the current consensus. Acta Neuropathol 123:465–472
21. Gibson P, Tong Y, Robinson G, Thompson MC, Currle DS,
Eden C et al (2010) Subtypes of medulloblastoma have distinct
developmental origins. Nature 468:1095–1099
22. Pei Y, Moore CE, Wang J, Tewari AK, Eroshkin A, Cho YJ et al
(2012) An animal model of MYC-driven medulloblastoma.
Cancer Cell 21:155–167
23. Rao G, Pedone CA, Coffin CM, Holland EC, Fults DW (2003)
c-Myc enhances sonic hedgehog-induced medulloblastoma for-
mation from nestin-expressing neural progenitors in mice.
Neoplasia 5:198–204
24. Read TA, Fogarty MP, Markant SL, McLendon RE, Wei Z,
Ellison DW et al (2009) Identification of CD15 as a marker for
tumor-propagating cells in a mouse model of medulloblastoma.
Cancer Cell 15:135–147
25. Schuller U, Heine VM, Mao J, Kho AT, Dillon AK, Han YG
et al (2008) Acquisition of granule neuron precursor identity is a
critical determinant of progenitor cell competence to form Shh-
induced medulloblastoma. Cancer Cell 14:123–134
26. Hooper CM, Hawes SM, Kees UR, Gottardo NG, Dallas PB
(2014) Gene expression analyses of the spatio-temporal rela-
tionships of human medulloblastoma subgroups during early
human neurogenesis. PLoS One 9:e112909
27. Batora NV, Sturm D, Jones DT, Kool M, Pfister SM, Northcott
PA (2014) Transitioning from genotypes to epigenotypes: why
the time has come for medulloblastoma epigenomics. Neuro-
science 264:171–185
28. Witt H, Mack SC, Ryzhova M, Bender S, Sill M, Isserlin R et al
(2011) Delineation of two clinically and molecularly distinct
subgroups of posterior fossa ependymoma. Cancer Cell
20:143–157
29. Mack SC, Witt H, Piro RM, Gu L, Zuyderduyn S, Stutz AM et al
(2014) Epigenomic alterations define lethal CIMP-positive
ependymomas of infancy. Nature 506:445–450
30. Johnson RA, Wright KD, Poppleton H, Mohankumar KM,
Finkelstein D, Pounds SB et al (2010) Cross-species genomics
matches driver mutations and cell compartments to model
ependymoma. Nature 466:632–636
31. Taylor MD, Poppleton H, Fuller C, Su X, Liu Y, Jensen P et al
(2005) Radial glia cells are candidate stem cells of ependymo-
ma. Cancer Cell 8:323–335
32. Bender S, Tang Y, Lindroth AM, Hovestadt V, Jones DT, Kool
M et al (2013) Reduced H3K27me3 and DNA hypomethylation
are major drivers of gene expression in K27M mutant pediatric
high-grade gliomas. Cancer Cell 24:660–672
33. Buczkowicz P, Hoeman C, Rakopoulos P, Pajovic S, Letourneau
L, Dzamba M et al (2014) Genomic analysis of diffuse intrinsic
pontine gliomas identifies three molecular subgroups and re-
current activating ACVR1 mutations. Nat Genet 46:451–456
34. Chan KM, Fang D, Gan H, Hashizume R, Yu C, Schroeder M
et al (2013) The histone H3.3K27M mutation in pediatric glioma
reprograms H3K27 methylation and gene expression. Genes
Dev 27:985–990
35. Fontebasso AM, Liu XY, Sturm D, Jabado N (2013) Chromatin
remodeling defects in pediatric and young adult glioblastoma: a
tale of a variant histone 3 tail. Brain Pathol 23:210–216
36. Khuong-Quang DA, Buczkowicz P, Rakopoulos P, Liu XY,
Fontebasso AM, Bouffet E et al (2012) K27 M mutation in
histone H3.3 defines clinically and biologically distinct sub-
groups of pediatric diffuse intrinsic pontine gliomas. Acta
Neuropathol 124:439–447
37. Schwartzentruber J, Korshunov A, Liu XY, Jones DT, Pfaff E,
Jacob K et al (2012) Driver mutations in histone H3.3 and
chromatin remodelling genes in paediatric glioblastoma. Nature
482:226–231
38. Venneti S, Garimella MT, Sullivan LM, Martinez D, Huse JT,
Heguy A et al (2013) Evaluation of histone 3 lysine 27
trimethylation (H3K27me3) and enhancer of Zest 2 (EZH2) in
pediatric glial and glioneuronal tumors shows decreased
H3K27me3 in H3F3A K27M mutant glioblastomas. Brain
Pathol 23:558–564
39. Wu G, Broniscer A, McEachron TA, Lu C, Paugh BS, Becksfort
J et al (2012) Somatic histone H3 alterations in pediatric diffuse
intrinsic pontine gliomas and non-brainstem glioblastomas. Nat
Genet 44:251–253
40. Parker M, Mohankumar KM, Punchihewa C, Weinlich R, Dal-
ton JD, Li Y et al (2014) C11orf95-RELA fusions drive
oncogenic NF-kappaB signalling in ependymoma. Nature
506:451–455
41. Warrington NM, Sun T, Luo J, McKinstry RC, Parkin PC,
Ganzhorn S et al (2015) The cyclic AMP pathway is a sex-
specific modifier of glioma risk in type I neurofibromatosis pa-
tients. Cancer Res 75:16–21
An integrative view on sex differences in brain tumors 3337
123
42. Norden AD, Wen PY, Kesari S (2005) Brain metastases. Curr
Opin Neurol 18:654–661
43. Smedby KE, Brandt L, Backlund ML, Blomqvist P (2009) Brain
metastases admissions in Sweden between 1987 and 2006. Br J
Cancer 101:1919–1924
44. Tabouret E, Chinot O, Metellus P, Tallet A, Viens P, Goncalves
A (2012) Recent trends in epidemiology of brain metastases: an
overview. Anticancer Res 32:4655–4662
45. Nayak L, Lee EQ, Wen PY (2012) Epidemiology of brain
metastases. Curr Oncol Reports 14:48–54
46. Hamilton A, Sibson NR (2013) Role of the systemic immune
system in brain metastasis. Mol Cell Neurosci 53:42–51
47. Soltermann A, Tischler V, Arbogast S, Braun J, Probst-Hensch
N, Weder W et al (2008) Prognostic significance of epithelial-
mesenchymal and mesenchymal-epithelial transition protein
expression in non-small cell lung cancer. Clin Cancer Res
14:7430–7437
48. Mikheev AM, Mikheeva SA, Trister AD, Tokita MJ, Emerson
SN, Parada CA et al (2014) Periostin is a novel therapeutic
target that predicts and regulates glioma malignancy. Neuro
Oncol 17:372–382
49. Cruz-Orengo L, Daniels BP, Dorsey D, Basak SA, Grajales-
Reyes JG, McCandless EE et al (2014) Enhanced sphingosine-1-
phosphate receptor 2 expression underlies female CNS au-
toimmunity susceptibility. J Clin Invest 124:2571–2584
50. Marosi C, Hassler M, Roessler K, Reni M, Sant M, Mazza E et al
(2008) Meningioma. Critical Rev Oncol/hematol 67:153–171
51. Guevara P, Escobar-Arriaga E, Saavedra-Perez D, Martinez-
Rumayor A, Flores-Estrada D, Rembao D et al (2010) Angio-
genesis and expression of estrogen and progesterone receptors as
predictive factors for recurrence of meningioma. J Neurooncol
98:379–384
52. Cea-Soriano L, Wallander MA, Garcia Rodriguez LA (2012)
Epidemiology of meningioma in the United Kingdom. Neu-
roepidemiology 39:27–34
53. Blitshteyn S, Crook JE, Jaeckle KA (2008) Is there an asso-
ciation between meningioma and hormone replacement therapy?
J Clin Oncol 26:279–282
54. Lusis EA, Scheithauer BW, Yachnis AT, Fischer BR, Chicoine
MR, Paulus W et al (2012) Meningiomas in pregnancy: a
clinicopathologic study of 17 cases. Neurosurgery 71:951–961
55. Cardenas-Goicoechea SJ, Debbs RH (2011) Meningioma during
pregnancy: a case report. J Reprod Med 56:81–84
56. DeGrood RM, Beemer WH, Fenner DE, Compton AA (1987) A
large meningioma presenting as a neurologic emergency in late
pregnancy. Obstet Gynecol 69:439–440
57. Patel S, Sharan V (2010) Meningioma in pregnancy. J Obstet
Gynaecol J Inst Obstet Gynaecol 30:56–57
58. Saitoh Y, Oku Y, Izumoto S, Go J (1989) Rapid growth of a
meningioma during pregnancy: relationship with estrogen and
progesterone receptors–case report. NeurolMedChir 29:440–443
59. Custer B, Longstreth WT Jr, Phillips LE, Koepsell TD, Van
Belle G (2006) Hormonal exposures and the risk of intracranial
meningioma in women: a population-based case-control study.
BMC Cancer 6:152
60. Korhonen K, Raitanen J, Isola J, Haapasalo H, Salminen T,
Auvinen A (2010) Exogenous sex hormone use and risk of
meningioma: a population-based case-control study in Finland.
Cancer Causes Control CCC 21:2149–2156
61. Li Q, Coulson H, Klaassen Z, Sharma S, Ramalingam P, Moses
KA et al (2013) Emerging association between androgen de-
privation therapy and male meningioma: significant expression
of luteinizing hormone-releasing hormone receptor in male
meningioma. Prostate Cancer Prostatic Dis 16:387–390
62. Cea-Soriano L, Blenk T, Wallander MA, Rodriguez LA (2012)
Hormonal therapies and meningioma: is there a link? Cancer
Epidemiol 36:198–205
63. Bergoglio MT, Gomez-Balaguer M, Almonacid Folch E, Hur-
tado Murillo F, Hernandez-Mijares A, Gomez-Balaguer M
(2013) Symptomatic meningioma induced by cross-sex hormone
treatment in a male-to-female transsexual. Endocrinologia y
nutricion : organo de la Sociedad Espanola de. Endocrinologia y
Nutricion 60:264–267
64. Deipolyi AR, Han SJ, Parsa AT (2010) Development of a
symptomatic intracranial meningioma in a male-to-female
transsexual after initiation of hormone therapy. J Clin Neurosci
Off J Neurosurg Soc Australas 17:1324–1326
65. Gazzeri R, Galarza M, Gazzeri G (2007) Growth of a menin-
gioma in a transsexual patient after estrogen-progestin therapy.
N Engl J Med 357:2411–2412
66. Cebula H, Pham TQ, Boyer P, Froelich S (2010) Regression of
meningiomas after discontinuation of cyproterone acetate in a
transsexual patient. Acta Neurochir (Wien) 152:1955–1956
67. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next
generation. Cell 144:646–674
68. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Mont-
gomery CA Jr, Butel JS et al (1992) Mice deficient for p53 are
developmentally normal but susceptible to spontaneous tu-
mours. Nature 356:215–221
69. Armstrong JF, Kaufman MH, Harrison DJ, Clarke AR (1995)
High-frequency developmental abnormalities in p53-deficient
mice. Curr Biol CB 5:931–936
70. Chen X, Watkins R, Delot E, Reliene R, Schiestl RH, Burgoyne
PS et al (2008) Sex difference in neural tube defects in p53-null
mice is caused by differences in the complement of X not Y
genes. Dev Neurobiol 68:265–273
71. Wang G, Fulkerson CM, Malek R, Ghassemifar S, Snyder PW,
Mendrysa SM (2012) Mutations in Lyar and p53 are synergis-
tically lethal in female mice. Birth Defects Res A 94:729–737
72. Tyner SD, Venkatachalam S, Choi J, Jones S, Ghebranious N,
Igelmann H et al (2002) p53 mutant mice that display early
ageing-associated phenotypes. Nature 415:45–53
73. Waskar M, Landis GN, Shen J, Curtis C, Tozer K, Abdueva D
et al (2009) Drosophila melanogaster p53 has developmental
stage-specific and sex-specific effects on adult life span
indicative of sexual antagonistic pleiotropy. Aging 1:903–936
74. Racagni G, Pezzotta S, Giordana MT, Iuliano E, Mocchetti I,
Spanu G et al (1983) Cyclic nucleotides in experimental and
human brain tumors. J Neurooncol 1:61–67
75. Goldhoff P, Warrington NM, Limbrick DD Jr, Hope A, Woerner
BM, Jackson E et al (2008) Targeted inhibition of cyclic AMP
phosphodiesterase-4 promotes brain tumor regression. Clin
Cancer Res 14:7717–7725
76. Warrington NM, Gianino SM, Jackson E, Goldhoff P, Garbow
JR, Piwnica-Worms D et al (2010) Cyclic AMP supppression is
sufficient to induce gliomagenesis in a mouse model of Neu-
rofibromatosis-1. Cancer Res 70:5717–5727
77. Yang L, Jackson E, Woerner BM, Perry A, Piwnica-Worms D,
Rubin JB (2007) Blocking CXCR4-mediated cyclic AMP sup-
pression inhibits brain tumor growth in vivo. Cancer Res
67:651–658
78. He X, Zhang L, Chen Y, Remke M, Shih D, Lu F et al (2014) The
G protein alpha subunit Galphas is a tumor suppressor in Sonic
hedgehog-driven medulloblastoma. Nat Med 20:1035–1042
79. Bajenaru ML, Hernandez MR, Perry A, Zhu Y, Parada LF,
Garbow JR et al (2003) Optic nerve glioma in mice requires
astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity.
Cancer Res 63:8573–8577
3338 T. Sun et al.
123
80. Sellner J, Kraus J, Awad A, Milo R, Hemmer B, Stuve O (2011)
The increasing incidence and prevalence of female multiple
sclerosis–a critical analysis of potential environmental factors.
Autoimmun Rev 10:495–502
81. van Vollenhoven RF (2009) Sex differences in rheumatoid
arthritis: more than meets the eye. BMC Med 7:12
82. Weckerle CE, Niewold TB (2011) The unexplained female
predominance of systemic lupus erythematosus: clues from ge-
netic and cytokine studies. Clin Rev Allergy Immunol 40:42–49
83. Wang C, Dehghani B, Magrisso IJ, Rick EA, Bonhomme E,
Cody DB et al (2008) GPR30 contributes to estrogen-induced
thymic atrophy. Mol Endocrinol 22:636–648
84. Maret A, Coudert JD, Garidou L, Foucras G, Gourdy P, Krust A
et al (2003) Estradiol enhances primary antigen-specific CD4 T
cell responses and Th1 development in vivo. Essential role of
estrogen receptor alpha expression in hematopoietic cells. Eur J
Immunol 33:512–521
85. Gourdy P, Araujo LM, Zhu R, Garmy-Susini B, Diem S, Laurell
H et al (2005) Relevance of sexual dimorphism to regulatory T
cells: estradiol promotes IFN-gamma production by invariant
natural killer T cells. Blood 105:2415–2420
86. Kissick HT, Sanda MG, Dunn LK, Pellegrini KL, On ST, Noel
JK et al (2014) Androgens alter T-cell immunity by inhibiting
T-helper 1 differentiation. Proc Natl Acad Sci USA 111:9887–
9892
87. Bianchi I, Lleo A, Gershwin ME, Invernizzi P (2012) The X
chromosome and immune associated genes. J Autoimmun
38:J187–J192
88. Schwarz JM, Bilbo SD (2012) Sex, glia, and development: in-
teractions in health and disease. Horm Behav 62:243–253
89. Benarroch EE (2013) Microglia: multiple roles in surveillance,
circuit shaping, and response to injury. Neurology 81:1079–
1088
90. Alliot F, Godin I, Pessac B (1999) Microglia derive from pro-
genitors, originating from the yolk sac, and which proliferate in
the brain. Brain Res Dev Brain Res 117:145–152
91. Cunningham CL, Martinez-Cerdeno V, Noctor SC (2013) Mi-
croglia regulate the number of neural precursor cells in the
developing cerebral cortex. J Neurosci Off J Soc Neurosci
33:4216–4233
92. Schafer DP, Lehrman EK, Kautzman AG, Koyama R, Mardinly
AR, Yamasaki R et al (2012) Microglia sculpt postnatal neural
circuits in an activity and complement-dependent manner.
Neuron 74:691–705
93. Walton NM, Sutter BM, Laywell ED, Levkoff LH, Kearns SM,
Marshall GP 2nd et al (2006) Microglia instruct subventricular
zone neurogenesis. Glia 54:815–825
94. Engler JR, Robinson AE, Smirnov I, Hodgson JG, Berger MS,
Gupta N et al (2012) Increased microglia/macrophage gene
expression in a subset of adult and pediatric astrocytomas. PLoS
One 7:e43339
95. Bettinger I, Thanos S, Paulus W (2002) Microglia promote
glioma migration. Acta Neuropathol 103:351–355
96. Markovic DS, Vinnakota K, Chirasani S, Synowitz M, Raguet
H, Stock K et al (2009) Gliomas induce and exploit microglial
MT1-MMP expression for tumor expansion. Proc Natl Acad Sci
USA 106:12530–12535
97. Ye XZ, Xu SL, Xin YH, Yu SC, Ping YF, Chen L et al (2012)
Tumor-associated microglia/macrophages enhance the invasion
of glioma stem-like cells via TGF-beta1 signaling pathway.
J Immunol 189:444–453
98. Hussain SF, Yang D, Suki D, Aldape K, Grimm E, Heimberger
AB (2006) The role of human glioma-infiltrating mi-
croglia/macrophages in mediating antitumor immune responses.
Neuro Oncol 8:261–279
99. Hussain SF, Yang D, Suki D, Grimm E, Heimberger AB (2006)
Innate immune functions of microglia isolated from human
glioma patients. J Transl Med 4:15
100. Kees T, Lohr J, Noack J, Mora R, Gdynia G, Todt G et al (2012)
Microglia isolated from patients with glioma gain antitumor
activities on poly (I:C) stimulation. Neuro Oncol 14:64–78
101. Galarneau H, Villeneuve J, Gowing G, Julien JP, Vallieres L
(2007) Increased glioma growth in mice depleted of macro-
phages. Cancer Res 67:8874–8881
102. Lenz KM, McCarthy MM (2014) A starring role for Microglia
in brain sex differences. Neurosci Rev J Bring Neurobiol Neurol
Psychiat
103. Lenz KM, Nugent BM, Haliyur R, McCarthy MM (2013) Mi-
croglia are essential to masculinization of brain and behavior.
J Neurosci Off J Soc Neurosci 33:2761–2772
104. Schwarz JM, Sholar PW, Bilbo SD (2012) Sex differences in
microglial colonization of the developing rat brain. J Neurochem
120:948–963
105. Santos-Galindo M, Acaz-Fonseca E, Bellini MJ, Garcia-Segura
LM (2011) Sex differences in the inflammatory response of
primary astrocytes to lipopolysaccharide. Biol Sex Differ 2:7
106. Maffini MV, Soto AM, Calabro JM, Ucci AA, Sonnenschein C
(2004) The stroma as a crucial target in rat mammary gland
carcinogenesis. J Cell Sci 117:1495–1502
107. Dolberg DS, Hollingsworth R, Hertle M, Bissell MJ (1985)
Wounding and its role in RSV-mediated tumor formation. Sci-
ence 230:676–678
108. Stewart TA, Mintz B (1981) Successive generations of mice
produced from an established culture line of euploid teratocar-
cinoma cells. Proc Natl Acad Sci USA 78:6314–6318
109. Zuk M, Stoehr AM (2010) Sex differences in susceptibility to
infection: an evolutionary perspective. Klein SRC (ed) Springer,
Berlin
110. Bize P, Criscuolo F, Metcalfe NB, Nasir L, Monaghan P (2009)
Telomere dynamics rather than age predict life expectancy in the
wild. Proc Biol Sci Royal Soc 276:1679–1683
111. Barrett EL, Richardson DS (2011) Sex differences in telomeres
and lifespan. Aging Cell 10:913–921
112. Kyo S, Takakura M, Kanaya T, Zhuo W, Fujimoto K, Nishio Y
et al (1999) Estrogen activates telomerase. Cancer Res 59:5917–
5921
113. Alonso-Alvarez C, Bertrand S, Faivre B, Chastel O, Sorci G
(2007) Testosterone and oxidative stress: the oxidation handicap
hypothesis. Proc Biol Sci Royal Soc 274:819–825
114. Vina J, Borras C, Gambini J, Sastre J, Pallardo FV (2005) Why
females live longer than males: control of longevity by sex
hormones. Sci Aging Knowledge Environ SAGE KE 2005:pe17
115. Tower J (2006) Sex-specific regulation of aging and apoptosis.
Mech Ageing Dev 127:705–718
116. Camus MF, Clancy DJ, Dowling DK (2012) Mitochondria,
maternal inheritance, and male aging. Curr Biol CB 22:1717–
1721
117. Frank SA, Hurst LD (1996) Mitochondria and male disease.
Nature 383:224
118. Gemmell NJ, Metcalf VJ, Allendorf FW (2004) Mother’s curse:
the effect of mtDNA on individual fitness and population via-
bility. Trends Ecol Evol 19:238–244
119. Tower J, Arbeitman M (2009) The genetics of gender and life
span. J Biol 8:38
120. Wolff JN, Gemmell NJ (2013) Mitochondria, maternal in-
heritance, and asymmetric fitness: why males die younger.
BioEssays News Rev Mol Cell Develop Biol 35:93–99
121. Maklakov AA, Bonduriansky R, Brooks RC (2009) Sex differ-
ences, sexual selection, and ageing: an experimental evolution
approach. Evol Int J Organic Evol 63:2491–2503
An integrative view on sex differences in brain tumors 3339
123
122. Lehto HR, Lehto S, Havulinna AS, Salomaa V (2013) Does the
clinical spectrum of incident cardiovascular disease differ be-
tween men and women? Eur J Prev Cardiol 21:964–971
123. Intapad S, Ojeda NB, Dasinger JH, Alexander BT (2014) Sex
differences in the developmental origins of cardiovascular dis-
ease. Physiology 29:122–132
124. Resanovic I, Rizzo M, Zafirovic S, Bjelogrlic P, Perovic M, Savic
K et al. (2013) Anti-atherogenic effects of 17beta-estradiol.
Hormone and metabolic research = Hormon- und Stoffwech-
selforschung = Hormones et metabolisme 45: 701-708
125. Khalil RA (2013) Estrogen, vascular estrogen receptor and
hormone therapy in postmenopausal vascular disease. Biochem
Pharmacol 86:1627–1642
126. Asscheman H, Giltay EJ, Megens JA, de Ronde WP, van
Trotsenburg MA, Gooren LJ (2011) A long-term follow-up
study of mortality in transsexuals receiving treatment with
cross-sex hormones. Eur J Endocrinol Eur Fed Endocr Soc
164:635–642
127. Zhao J, Zhu S, Sun L, Meng F, Zhao L, Zhao Y et al (2014)
Androgen deprivation therapy for prostate cancer is associated
with cardiovascular morbidity and mortality: a meta-analysis of
population-based observational studies. PLoS One 9:e107516
128. Brooks MD, Sengupta R, Snyder SC, Rubin JB (2013) Hitting
them where they live: targeting the glioblastoma perivascular
stem cell niche. Curr Pathobiol Rep 1:101–110
129. Charles N, Ozawa T, Squatrito M, Bleau AM, Brennan CW,
Hambardzumyan D et al (2010) Perivascular nitric oxide acti-
vates notch signaling and promotes stem-like character in
PDGF-induced glioma cells. Cell Stem Cell 6:141–152
130. Arnold AP (2012) The end of gonad-centric sex determination in
mammals. Trends in Genet TIG 28:55–61
131. Barker DJ (2004) Developmental origins of adult health and
disease. J Epidemiol Community Health 58:114–115
132. Tsunoda Y, Tokunaga T, Sugie T (1985) Altered sex ratio of
live young after transfer of fast- and slow-developing mouse
embryos. Gamete Res 12:301–304
133. Ray PF, Conaghan J, Winston RM, Handyside AH (1995) In-
creased number of cells and metabolic activity in male human
preimplantation embryos following in vitro fertilization. J Re-
prod Fertil 104:165–171
134. Gutierrez-Adan A, Perez-Crespo M, Fernandez-Gonzalez R,
Ramirez MA, Moreira P, Pintado B et al (2006) Developmental
consequences of sexual dimorphism during pre-implantation
embryonic development. Reprod Domestic Animals Zuchthy-
giene 41(Suppl 2):54–62
135. Tagirov M, Rutkowska J (2014) Sexual dimorphism in the early
embryogenesis in zebra finches. PLoS One 9:e114625
136. Tiffin GJ, Rieger D, Betteridge KJ, Yadav BR, King WA (1991)
Glucose and glutamine metabolism in pre-attachment cattle
embryos in relation to sex and stage of development. J Reprod
Fertil 93:125–132
137. Gutierrez-Adan A, Granados J, Pintado B, De La Fuente J
(2001) Influence of glucose on the sex ratio of bovine IVM/IVF
embryos cultured in vitro. Reprod Fertil Dev 13:361–365
138. Bermejo-Alvarez P, Rizos D, Rath D, Lonergan P, Gutierrez-Adan
A (2008) Epigenetic differences between male and female bovine
blastocysts produced in vitro. Physiol Genomics 32:264–272
139. Van Blerkom J (2008) Mitochondria as regulatory forces in
oocytes, preimplantation embryos and stem cells. Reprod
Biomed Online 16:553–569
140. Bredbacka K, Bredbacka P (1996) Glucose controls sex-related
growth rate differences of bovine embryos produced in vitro.
J Reprod Fertil 106:169–172
141. Krietsch WK, Fundele R, Kuntz GW, Fehlau M, Burki K, Ill-
mensee K (1982) The expression of X-linked phosphoglycerate
kinase in the early mouse embryo. Differentiation Res Biol
Diver 23:141–144
142. Williams TJ (1986) A technique for sexing mouse embryos by a
visual colorimetric assay of the X-linked enzyme, glucose
6-phosphate dehydrogenase. Theriogenology 25:733–739
143. Kimura K, Iwata H, Thompson JG (2008) The effect of glu-
cosamine concentration on the development and sex ratio of
bovine embryos. Animal Reprod Sci 103:228–238
144. Gardner DK, Leese HJ (1987) Assessment of embryo viability
prior to transfer by the noninvasive measurement of glucose
uptake. J Exp Zool 242:103–105
145. Burgoyne PS (1993) A Y-chromosomal effect on blastocyst cell
number in mice. Development 117:341–345
146. Pergament E, Fiddler M, Cho N, Johnson D, Holmgren WJ
(1994) Sexual differentiation and preimplantation cell growth.
Hum Reprod 9:1730–1732
147. Kishton RJ, Rathmell JC (2015) Novel therapeutic targets of
tumor metabolism. Cancer J 21:62–69
148. Khulan B, Cooper WN, Skinner BM, Bauer J, Owens S, Prentice
AM et al (2012) Periconceptional maternal micronutrient sup-
plementation is associated with widespread gender related
changes in the epigenome: a study of a unique resource in the
Gambia. Hum Mol Genet 21:2086–2101
149. McKay JA, Wong YK, Relton CL, Ford D, Mathers JC
(2011) Maternal folate supply and sex influence gene-specific
DNA methylation in the fetal gut. Mol Nutr Food Res 55:
1717–1723
150. Baserga M, Kaur R, Hale MA, Bares A, Yu X, Callaway
CW et al (2010) Fetal growth restriction alters transcription
factor binding and epigenetic mechanisms of renal 11beta-
hydroxysteroid dehydrogenase type 2 in a sex-specific man-
ner. Am J Physiol Regul Integr Comp Physiol 299:R334–
R342
151. Bermejo-Alvarez P, Rizos D, Rath D, Lonergan P, Gutierrez-
Adan A (2010) Sex determines the expression level of one third
of the actively expressed genes in bovine blastocysts. Proc Natl
Acad Sci USA 107:3394–3399
152. Xu Q, Yang C, Du Y, Chen Y, Liu H, Deng M et al (2014)
AMPK regulates histone H2B O-GlcNAcylation. Nucleic Acids
Res 42:5594–5604
153. Forma E, Jozwiak P, Brys M, Krzeslak A (2014) The potential
role of O-GlcNAc modification in cancer epigenetics. Cell Mol
Biol Lett 19:438–460
154. Van der Meulen J, Speleman F, Van Vlierberghe P (2014) The
H3K27me3 demethylase UTX in normal development and dis-
ease. Epigenetics Off J DNA Methyl Soc 9:658–668
155. Greenfield A, Carrel L, Pennisi D, Philippe C, Quaderi N,
Siggers P et al (1998) The UTX gene escapes X inactivation in
mice and humans. Hum Mol Genet 7:737–742
156. Walport LJ, Hopkinson RJ, Vollmar M, Madden SK, Gileadi C,
Oppermann U et al (2014) Human UTY(KDM6C) is a male-
specific N-methyl lysyl demethylase. J Biol Chem 289:18302–
18313
157. Van der Meulen J, Sanghvi V, Mavrakis K, Durinck K, Fang F,
Matthijssens F et al (2015) The H3K27me3 demethylase UTX is
a gender-specific tumor suppressor in T-cell acute lymphoblastic
leukemia. Blood 125:13–21
158. Brockdorff N (2011) Chromosome silencing mechanisms in
X-chromosome inactivation: unknown unknowns. Development
138:5057–5065
159. Chaligne R, Heard E (2014) X-chromosome inactivation in
development and cancer. FEBS Lett 588:2514–2522
160. Arthold S, Kurowski A, Wutz A (2011) Mechanistic insights
into chromosome-wide silencing in X inactivation. Hum Genet
130:295–305
3340 T. Sun et al.
123
161. Deng X, Berletch JB, Nguyen DK, Disteche CM (2014) X
chromosome regulation: diverse patterns in development, tissues
and disease. Nat Rev Genet 15:367–378
162. Deuve JL, Avner P (2011) The coupling of X-chromosome in-
activation to pluripotency. Annu Rev Cell Dev Biol 27:611–629
163. Yildirim E, Kirby JE, Brown DE, Mercier FE, Sadreyev RI,
Scadden DT et al (2013) Xist RNA is a potent suppressor of
hematologic cancer in mice. Cell 152:727–742
164. Gabory A, Ferry L, Fajardy I, Jouneau L, Gothie JD, Vige A
et al (2012) Maternal diets trigger sex-specific divergent tra-
jectories of gene expression and epigenetic systems in mouse
placenta. PLoS One 7:e47986
165. Barker DJ, Lampl M, Roseboom T, Winder N (2012) Resource
allocation in utero and health in later life. Placenta 33(Suppl
2):e30–e34
166. Stark MJ, Dierkx L, Clifton VL, Wright IM (2006) Alterations
in the maternal peripheral microvascular response in pregnan-
cies complicated by preeclampsia and the impact of fetal sex.
J Soc Gynecol Investig 13:573–578
167. Stark MJ, Clifton VL, Wright IM (2009) Neonates born to
mothers with preeclampsia exhibit sex-specific alterations in
microvascular function. Pediatr Res 65:292–295
168. Borzsonyi B, Demendi C, Nagy Z, Toth K, Csanad M, Pajor
A et al (2011) Gene expression patterns of insulin-like
growth factor 1, insulin-like growth factor 2 and insulin-like
growth factor binding protein 3 in human placenta from
pregnancies with intrauterine growth restriction. J Perinat
Med 39:701–707
169. Scott NM, Hodyl NA, Murphy VE, Osei-Kumah A, Wyper H,
Hodgson DM et al (2009) Placental cytokine expression co-
varies with maternal asthma severity and fetal sex. J Immunol
182:1411–1420
170. Goldenberg RL, Andrews WW, Faye-Petersen OM, Goepfert
AR, Cliver SP, Hauth JC (2006) The Alabama Preterm Birth
Study: intrauterine infection and placental histologic findings in
preterm births of males and females less than 32 weeks. Am J
Obstet Gynecol 195:1533–1537
171. Howerton CL, Morgan CP, Fischer DB, Bale TL (2013)
O-GlcNAc transferase (OGT) as a placental biomarker of ma-
ternal stress and reprogramming of CNS gene transcription in
development. Proc Natl Acad Sci USA 110:5169–5174
172. Phoenix CH, Goy RW, Gerall AA, Young WC (1959) Orga-
nizing action of prenatally administered testosterone propionate
on the tissues mediating mating behavior in the female guinea
pig. Endocrinology 65:369–382
173. McCarthy MM (2008) Estradiol and the developing brain.
Physiol Rev 88:91–124
174. Giedd JN, Raznahan A, Mills KL, Lenroot RK (2012) Review:
magnetic resonance imaging of male/female differences in hu-
man adolescent brain anatomy. Biol Sex Differ 3:19
175. Tiemeier H, Lenroot RK, Greenstein DK, Tran L, Pierson R,
Giedd JN (2010) Cerebellum development during childhood and
adolescence: a longitudinal morphometric MRI study. NeuroI-
mage 49:63–70
176. Belcher SM (2009) Blockade of estrogen receptor signaling to
improve outlook for medulloblastoma sufferers. Future Oncol
5:751–754
177. Mancuso M, Leonardi S, Ceccarelli M, Pasquali E, De Stefano I,
Prisco MG et al (2010) Protective role of 17 beta-estradiol on
medulloblastoma development in Patched 1 heterozygous mice.
Int J Cancer J Int du Cancer 127:2749–2757
178. Cookman CJ, Belcher SM (2015) Estrogen Receptor beta
Upregulates IGF1R Expression and Activity to Inhibit Apopto-
sis and Increase Growth of Medulloblastoma. Endocrinology
en20151141
179. Schedin P (2006) Pregnancy-associated breast cancer and
metastasis. Nat Rev Cancer 6:281–291
180. Fugazzola L, Cirello V, Beck-Peccoz P (2011) Fetal mi-
crochimerism as an explanation of disease. Nature Rev
Endocrinol 7:89–97
181. Kamper-Jorgensen M, Biggar RJ, Tjonneland A, Hjalgrim H,
Kroman N, Rostgaard K et al (2012) Opposite effects of mi-
crochimerism on breast and colon cancer. Eur J Cancer
48:2227–2235
182. Cirello V, Perrino M, Colombo C, Muzza M, Filopanti M, Vi-
centini L et al (2010) Fetal cell microchimerism in papillary
thyroid cancer: studies in peripheral blood and tissues. Int J
Cancer J Int du Cancer 126:2874–2878
183. Nguyen Huu S, Oster M, Avril MF, Boitier F, Mortier L,
Richard MA et al. (2009) Fetal microchimeric cells participate
in tumour angiogenesis in melanomas occurring during preg-
nancy. Am J Pathol 174: 630-7
184. Dubernard G, Oster M, Chareyre F, Antoine M, Rouzier R, Uzan
S et al (2009) Increased fetal cell microchimerism in high grade
breast carcinomas occurring during pregnancy. Int J Cancer J Int
du Cancer 124:1054–1059
185. Gadi VK, Nelson JL (2007) Fetal microchimerism in women
with breast cancer. Cancer Res 67:9035–9038
186. Crespi BJ, Summers K (2006) Positive selection in the evolution
of cancer. Biol Rev Camb Philos Soc 81:407–424
187. Tomasetti C, Vogelstein B (2015) Cancer etiology. Variation in
cancer risk among tissues can be explained by the number of
stem cell divisions. Science 347:78–81
188. CBTRUS (2010) CBTRUS statistical report: primary brain and
central nervous System tumors diagnosed in the United States in
2004–2006
189. Leroi AM, Koufopanou V, Burt A (2003) Cancer selection.
Nature Rev Cancer 3:226–231
190. Coetzee G, Irvine R (2002) Size of the androgen receptor CAG
repeat and prostate cancer: does it matter? J Clin Oncol
20:3572–3573
191. Adler MI, Bonduriansky R (2014) Sexual conflict, life span, and
aging. Cold Spring Harbor Persp Biology 6
192. Edmondson RJ, Monaghan JM, Davies BR (2002) The human
ovarian surface epithelium is an androgen responsive tissue. Br J
Cancer 86:879–885
193. Ilekis JV, Connor JP, Prins GS, Ferrer K, Niederberger C, Scoccia
B (1997) Expression of epidermal growth factor and androgen
receptors in ovarian cancer. Gynecol Oncol 66:250–254
194. Silva EG, Tornos C, Fritsche HA, Jr., el-Naggar A, Gray K,
Ordonez NG et al. (1997) The induction of benign epithelial
neoplasms of the ovaries of guinea pigs by testosterone
stimulation: a potential animal model. Modern Pathol Off J US
Can Acad Pathol Inc 10: 879–883
195. Risch HA (1998) Hormonal etiology of epithelial ovarian can-
cer, with a hypothesis concerning the role of androgens and
progesterone. J Natl Cancer Inst 90:1774–1786
196. Smith NG, Hurst LD (1998) Molecular evolution of an im-
printed gene: repeatability of patterns of evolution within the
mammalian insulin-like growth factor type II receptor. Genetics
150:823–833
197. Giovannucci E (2003) Nutrition, insulin, insulin-like growth factors
and cancer. Hormone and metabolic research = Hormon- und
Stoffwechselforschung = Hormones et metabolisme 35: 694–704
198. Tycko B, Morison IM (2002) Physiological functions of im-
printed genes. J Cell Physiol 192:245–258
199. Hernandez L, Kozlov S, Piras G, Stewart CL (2003) Paternal
and maternal genomes confer opposite effects on proliferation,
cell-cycle length, senescence, and tumor formation. Proc Natl
Acad Sci USA 100:13344–13349
An integrative view on sex differences in brain tumors 3341
123
200. Bloom HJ, Peckham MJ, Richardson AE, Alexander PA, Payne
PM (1973) Glioblastoma multiforme: a controlled trial to assess
the value of specific active immunotherapy in patients treated by
radical surgery and radiotherapy. Br J Cancer 27:253–267
201. Amlin-Van Schaick JC, Kim S, DiFabio C, Lee MH, Broman
KW, Reilly KM (2012) Arlm1 is a male-specific modifier of
astrocytoma resistance on mouse Chr 12. Neuro-oncology
14:160–174
202. Reilly KM, Tuskan RG, Christy E, Loisel DA, Ledger J,
Bronson RT et al (2004) Susceptibility to astrocytoma in mice
mutant for Nf1 and Trp53 is linked to chromosome 11 and
subject to epigenetic effects. Proc Natl Acad Sci USA
101:13008–13013
203. Walrath JC, Fox K, Truffer E (2009) Gregory Alvord W, Qui-
nones OA, Reilly KM. Chr 19(A/J) modifies tumor resistance in
a sex- and parent-of-origin-specific manner. Mamm Genome
20:214–223
204. Zhu Y, Guignard F, Zhao D, Liu L, Burns DK, Mason RP et al
(2005) Early inactivation of p53 tumor suppressor gene coop-
erating with NF1 loss induces malignant astrocytoma. Cancer
Cell 8:119–130
205. Plunkett RJ, Lis A, Barone TA, Fronckowiak MD, Greenberg SJ
(1999) Hormonal effects on glioblastoma multiforme in the
nude rat model. J Neurosurg 90:1072–1077
206. Sareddy GR, Nair BC, Gonugunta VK, Zhang QG, Brenner A,
Brann DW et al (2012) Therapeutic significance of estrogen
receptor beta agonists in gliomas. Mol Cancer Ther 11:1174–
1182
207. Arnold AP, Chen X (2009) What does the ‘‘four core geno-
types’’ mouse model tell us about sex differences in the brain
and other tissues? Front Neuroendocrinol 30:1–9
208. Arnold AP (2014) Conceptual frameworks and mouse models
for studying sex differences in physiology and disease: why
compensation changes the game. Exp Neurol 259:2–9
209. Wolstenholme JT, Rissman EF, Bekiranov S (2013) Sexual
differentiation in the developing mouse brain: contributions of
sex chromosome genes. Genes Brain Behav 12:166–180
210. Werler S, Poplinski A, Gromoll J, Wistuba J (2011) Expression
of selected genes escaping from X inactivation in the 41,
XX(Y)* mouse model for Klinefelter’s syndrome. Acta Paediatr
100:885–891
211. Case LK, Wall EH, Dragon JA, Saligrama N, Krementsov DN,
Moussawi M et al (2013) The Y chromosome as a regulatory
element shaping immune cell transcriptomes and susceptibility
to autoimmune disease. Genome Res 23:1474–1485
212. Do TN, Ucisik-Akkaya E, Davis CF, Morrison BA, Dorak MT
(2009) TP53 R72P and MDM2 SNP309 polymorphisms in
modification of childhood acute lymphoblastic leukemia sus-
ceptibility. Cancer Genet Cytogenet 195:31–36
213. Firoz EF, Warycha M, Zakrzewski J, Pollens D, Wang G,
Shapiro R et al (2009) Association of MDM2 SNP309, age of
onset, and gender in cutaneous melanoma. Clin Cancer Res
15:2573–2580
214. Bond GL, Hirshfield KM, Kirchhoff T, Alexe G, Bond EE,
Robins H et al (2006) MDM2 SNP309 accelerates tumor for-
mation in a gender-specific and hormone-dependent manner.
Cancer Res 66:5104–5110
3342 T. Sun et al.
123
